Skip to NavigationSkip to content

GSK's Andrew Witty appointed president of EFPIA

Published on: 05/01/10

GlaxoSmithKline chief executive Andrew Witty has been appointed president of EFPIA.

He previously served as vice-president of the European industry association for two years and takes over the role of president from Bayer Healthcare's chief executive Arthur Higgins, 

Witty said: “I am pleased to have the opportunity to represent our industry in Europe at this challenging time, when the policy considerations of healthcare have probably never been more pertinent.

“Europe needs a 21st century approach to healthcare; one that provides access to optimal and equitable quality of care in a manner that is sustainable. We need policies that make this a reality, as well as policies that recognize innovation, equipping us to develop new medicines and therapies that citizens seek.”

Witty became chief executive GlaxoSmithKline in May 2008, having previously been GSK’s president of pharmaceuticals Europe, and has been with the company for 25 years.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches